Spinal Cord Diseases

Peer Reviewed News for Medical Professionals

Medical Research Health Special Topics World

Home

	Health
	Aging
	Asian Health
	Events
	Fitness
	Food & Nutrition
	Happiness
	Men's Health
	Mental Health
	Occupational Health
	Parenting
	Public Health
	Sleep Hygiene
	Women's Health

	Healthcare
	Africa
	Australia
	Canada Healthcare
	China Healthcare
	India Healthcare
	New Zealand
	South Africa
	UK
	USA
	World Healthcare

	Latest Research
	Aging
	Alternative Medicine
	Anaethesia
	Biochemistry
	Biotechnology
	Cancer
	Cardiology
	Clinical Trials
	Cytology
	Dental
	Dermatology
	Embryology
	Endocrinology
	ENT
	Environment
	Epidemiology
	Gastroenterology
	Genetics
	Gynaecology
	Haematology
	Immunology
	Infectious Diseases
	Medicine
	Metabolism
	Microbiology
	Musculoskeletal
	Nephrology
	Neurosciences
	Brain Diseases
	Demyelinating Diseases
	Headache
	Memory
	Neurochemistry
	Neurodegenerative Diseases
	Regeneration
	Spinal Cord Diseases
	Lou Gehrig's Disease
	Stroke
	Taste
	Trigeminal Neuralgia
	Obstetrics
	Ophthalmology
	Orthopedics
	Paediatrics
	Pathology
	Pharmacology
	Physiology
	Physiotherapy
	Psychiatry
	Radiology
	Rheumatology
	Sports Medicine
	Surgery
	Toxicology
	Urology

	Medical News
	Awards & Prizes
	Epidemics
	Launch
	Opinion
	Professionals

	Special Topics
	Ethics
	Euthanasia
	Evolution
	Feature
	Odd Medical News
	Climate

Advanced Search

Latest Research : Neurosciences : Spinal Cord Diseases
	Last Updated: Oct 10, 2010 - 6:10:51 AM

Latest Research : Neurosciences : Spinal Cord Diseases
Stem cells repair damaged spinal cord tissue

A joint study by Professor Jonas Frisén's research group at Karolinska Institutet and their colleagues from France and Japan, and published in Cell Stem Cell, shows how stem cells and several other cell types contribute to the formation of new spinal cord cells in mice and how this changes dramatically after trauma.

Oct 10, 2010 - 6:06:53 AM

Latest Research : Neurosciences : Spinal Cord Diseases : Lou Gehrig's Disease
Discoveries should aid research into cause of ALS

Two teams of researchers at Northwestern University have found a novel pathological hallmark of the neurodegenerative disease amyotrophic lateral sclerosis (ALS) at the molecular level. The neurologists and biochemists show how and why the mutated superoxide dismutase (SOD1) protein, which is associated with a familial form of ALS, becomes vulnerable and prone to aggregation and also provide evidence linking disease onset with the formation of intermolecular aggregates.
Apr 26, 2006 - 2:53:00 PM

Latest Research : Neurosciences : Spinal Cord Diseases : Lou Gehrig's Disease
First diagnostic indicator for Amytrophic Lateral Sclerosis (ALS) identified

Researchers from Mount Sinai School of Medicine identified three proteins that are found in significantly lower concentration in the cerebral spinal fluid of patients with ALS than in healthy individuals. These are the first biomarkers for this disease.
Feb 23, 2006 - 12:15:00 PM

Latest Research : Neurosciences : Spinal Cord Diseases : Lou Gehrig's Disease
Specific signaling link between neurons and muscles in the fruit fly is essential for keeping the nervous system stable.

A UCSF study has found that a specific signaling link between neurons and muscles in the fruit fly is essential for keeping the insect's nervous system stable.
Sep 4, 2005 - 7:20:00 AM

Latest Research : Neurosciences : Spinal Cord Diseases : Lou Gehrig's Disease
Mutant Cu/Zn superoxide dismutase (SOD1) enzymes implicated in Lou Gehrig's disease

A new study indicates that mutant Cu/Zn superoxide dismutase (SOD1) enzymes that are associated with an inherited form of Lou Gehrig's disease cause the protein to become sticky in tissues. Partial unfolding of the mutant protein can expose hydrophobic residues that may promote abnormal interactions with other proteins or membranes in the cell.
Aug 11, 2005 - 2:51:00 AM

Latest Research : Neurosciences : Spinal Cord Diseases : Lou Gehrig's Disease
Arimoclomol Significantly Inhibits Progression of Amyotrophic Lateral Sclerosis

CytRx Corporation (Nasdaq: CYTR - News) today announced the completion of a meeting with representatives of the U.S. Food and Drug Administration (FDA) prior to the submission of the Company's Investigational New Drug (IND) application for its lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). The FDA's pre-IND meeting programs are designed to provide sponsors with advance guidance and input on drug development programs.
Apr 20, 2005 - 9:24:00 AM

<< prev next >>